Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals

    - New Partnership Introduces Invisicare to China

    LAS VEGAS and PLAINSBORO, N.J., Feb. 4 /PRNewswire-FirstCall/ --
Skinvisible, Inc. (OTC Bulletin Board:   SKVI), the developers of Invisicare, a
patented polymer delivery system that provides life cycle management for
topical products, and RHEI Pharmaceuticals NV, a Belgium based pharmaceutical
company that in-licenses drugs for sale in China, today announced they have
signed a first option agreement. This agreement gives RHEI the first option to
license the exclusive rights for Skinvisible's dermatology products for the
territory of China, Hong Kong and Taiwan. Specifically the agreement is for
over-the-counter and prescription dermatology products formulated with
Invisicare that have been approved in a reference country. Terms of the
agreement were not disclosed.  As part of the agreement, RHEI will augment its
existing product lines by seeking approval and then marketing and
manufacturing Skinvisible's Invisicare dermatology products in the approved


    The Chinese pharmaceutical market represents a huge opportunity with an
estimated $22.6 billion spent on pharmaceutical drugs in 2007 and growing at
an annual rate of nearly 20%. To address this huge growth, the Chinese
government has implemented a more effective approval process, one that fits
advantageously into the strategic plans of both Skinvisible and RHEI.

    "Skinvisible looks forward to this collaboration with RHEI as we continue
to implement our strategy to pursue an accelerated expansion worldwide of
licensees for our dermatology formulations enhanced with Invisicare," said Mr.
Terry Howlett, President and CEO of Skinvisible.  "We are confident that RHEI
can leverage its regulatory expertise, marketing capabilities and distribution
channels to successfully commercialize Skinvisible products in the Chinese
market.  Additionally, we continue to focus on expanding our revenue base by
negotiating other international partnerships and licence agreements."

    "This partnership with Skinvisible allows RHEI to capitalize on the
benefits of their Invisicare technology platform and will diversify the
products offered by RHEI to the medical community," said Dr. Geert
Cauwenbergh, Chairman and CEO of RHEI Pharmaceuticals. "Building on our
demonstrated abilities at obtaining regulatory approvals and our experience in
the Chinese healthcare market, our strategic investment in the development of
an expanded dermatology product line formulated with Invisicare will be a
great asset to our company and its bottom-line."

    About Invisicare
    Invisicare is Skinvisible's patented polymer delivery system that offers
life-cycle management and unique enhancements for topically delivered
products.  It is a combination of hydrophilic and hydrophobic polymers that
hold active ingredients on the skin for extended periods of time resisting
both wash off and perspiration.  Invisicare can control the release of
actives, reduce irritation and can eliminate some costly manufacturing
processes.  It is non-occlusive and allows for normal skin respiration while
protecting against environmental irritants.

    About Skinvisible Pharmaceuticals, Inc.
    Skinvisible Pharmaceuticals is a research-and-development company whose
primary business objective is to license its proprietary formulations with
Invisicare to pharmaceutical and cosmeceutical companies as well as assisting
companies in enhancing their existing skin care products. Skinvisible receives
a combination of research and development fees, upfront license fees, and
ongoing royalties for the life of the Invisicare patent. Skinvisible's value
also lies in its ability to continually generate new IP on dermatology and
medical products formulated with Invisicare.

    About RHEI Pharmaceuticals
    RHEI Pharmaceuticals (RHEI) is a specialty pharmaceutical company focused
on bringing core medicines from the U.S., Europe and Japan, into the
fast-growing Chinese marketplace. RHEI in-licenses approved and late stage
pharmaceutical products from these reference countries, and applies its
development and regulatory expertise to bring these important therapies to
China. RHEI's internal capabilities encompass business development, regulatory
approval and clinical development - combining a western approach to
pharmaceuticals with Chinese professionals that are highly experienced in the

    Forward-Looking Statements:  This press release contains 'forward
looking' statements within the meaning of Section 21A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and are subject to the safe harbors created thereby. Such statements
involve certain risks and uncertainties associated with an emerging company.
Actual results could differ materially from those projected in the forward
looking statements as a result of risk factors discussed in Skinvisible, Inc.
reports on file with the U.S. Securities and Exchange Commission (including,
but not limited to, a report on Form 10Q for the quarter ending September 30,


    Corporate Contact:
    Doreen McMorran
    Skinvisible Pharmaceuticals, Inc.
    Phone: 702-433-7154


For further information:

For further information: Doreen McMorran of Skinvisible Pharmaceuticals,
Inc., +1-702-433-7154, Web Site:

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890